Please ensure Javascript is enabled for purposes of website accessibility
Testing Timeline: What’s Ahead for COVID-19 Vaccines
gvw_ap_news
By Associated Press
Published 4 years ago on
November 10, 2020

Share

Pfizer’s surprising news that its COVID-19 vaccine might offer more protection than anticipated — an announcement right after a fraught U.S. presidential election campaign — is raising questions about exactly how the different shots will make it to market.

Pfizer Inc. and the maker of the other leading U.S. vaccine candidate, Moderna Inc., have been cautioning for weeks that the earliest they could seek regulatory approval for wider use of their shots would be late November. In Britain, AstraZeneca recently said it hoped to prove its own vaccine was effective by year’s end.

Late on Monday in a series of tweets President Donald Trump accused the U.S. Food and Drug Administration and Pfizer of waiting until after the election to announce its positive vaccine news for political reasons. Pfizer did not receive data from independent trial monitors until Sunday, however. The FDA was not involved in Pfizer’s decision to announce its early results and made no announcements of its own.

The hard truth: Science moves at its own pace. While COVID-19 vaccines are being developed at record speeds in hope of ending the pandemic, when they’re ready for prime time depends on a long list of research steps including how many study volunteers wind up getting the coronavirus — something scientists cannot control.

Here’s a look at the process:

How the Studies Work

Pfizer and its German partner BioNTech have enrolled nearly 44,000 people in final testing of their vaccine. Neither participants, their doctors nor Pfizer know who gets the real vaccine and who gets a dummy shot. They get a second dose about three weeks after the first.

And then another week after the second dose, key tracking begins: Counting anyone who experiences COVID-19 symptoms and tests positive for the virus as participants go about their daily routines, especially in hot spots.

Late-stage testing of other vaccine candidates is similar, varying slightly in the number of volunteers and timing.

How to Tell Shots Work

Every vaccine study is overseen by an independent “data and safety monitoring board,” or DSMB. These boards include scientists and statisticians who have no ties to the vaccine makers.

Before a study is complete, only the DSMB has the power to unlock the code of who got real vaccine and who got placebo, and to recommend if the shots are working well enough to stop testing early.

Those boards take sneak peeks at pre-determined times agreed to by the manufacturer and the Food and Drug Administration. The first interim analysis for Pfizer came Sunday. The company reported its data monitors had counted 94 infections so far — and that among those initial cases, the vaccine appeared 90% effective.

But the study isn’t stopping: To be sure of protection, it’s set to run until there are 164 infections. The more COVID-19 cases occur in the trial, the better idea scientists will have of just how protective the shots really are.

FILE – In this Monday, Nov. 23, 2015, file photo, the Pfizer logo is displayed at world headquarters in New York. On Monday, Nov. 9, 2020, Pfizer said an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19. (AP Photo/Mark Lennihan, File)

Could That Sneak Peek Come Earlier?

Pfizer’s initial plans called for evaluating when just 32 infections had been counted. But many scientists warned that was simply too small to draw conclusions about a vaccine needed by billions.

Pfizer said it reconsidered, going back to the FDA for permission to change the plan and do its first interim analysis when there were more cases. By the time Pfizer made the change and caught up with a backlog of virus tests, the DSMB had 94 infections to analyze.

The higher number increases confidence in those still preliminary results, said Dr. Jesse Goodman, a former FDA vaccine scientist now at Georgetown University.

Moderna, AstraZeneca and other companies not quite as far along in their final testing all have set slightly different timepoints for when their data monitors will peek at how the shots are working.

Don’t Forget Safety

Safety is the top priority. Monitors also watch for unexpected or serious side effects. Earlier this fall, separate studies of vaccine candidates made by AstraZeneca and Johnson & Johnson were temporarily halted after some participants experienced health problems, delaying the research until safety investigations allowed both to resume.

Pfizer said Monday no serious safety concerns have emerged so far with its vaccine.

But the FDA is requiring that companies track at least half of study volunteers for two months to look for side effects before asking the agency to review their vaccine. That’s about when side effects have cropped in studies of other vaccines.

Pfizer and Moderna both expect to reach that safety milestone later in November.

What Happens Then?

Companies are expected to seek permission for “emergency use” of their vaccines, rather than waiting to fully complete their studies and then seeking traditional approval.

The FDA’s scientific advisers will debate each company’s study findings in a public meeting before the agency decides.

Manufacturers already have begun stockpiling vaccine doses in anticipation of eventual approval, but the first shots will be in short supply and rationed. And the first people vaccinated will need to undergo extra safety tracking, as the government watches for rare side effects that might crop up when the shots are given to many more people than were in the research studies.

RELATED TOPICS:

DON'T MISS

5 Reasons Early Voting Is Overwhelmed With Falsehoods

DON'T MISS

Christian McCaffrey Returns to Practice for the 49ers From Achilles Tendon Injury

DON'T MISS

California Sues LA Suburb for Temporary Ban of Homeless Shelters

DON'T MISS

You May Have Blocked Someone on X but Now They Can See Your Public Posts Anyway

DON'T MISS

Some Republican-Led States Refuse to Let Justice Department Monitors Into Polling Places

DON'T MISS

Fresno Police Arrest Suspect in Fatal NW Apartment Shooting

DON'T MISS

Fresno Murder Suspect Stopped in Las Vegas, Others Wanted

DON'T MISS

Trump’s Crowds Are Dwindling as His Campaign Winds Down

DON'T MISS

Trump Threatens 25% Tariff on Mexico to Curb Immigration

DON'T MISS

Music Legend Quincy Jones, Architect of Pop’s Greatest Hits, Dies at 91

UP NEXT

North Korea’s Long-Range Missile Test Signals Its Improved, Potential Capability to Attack US

UP NEXT

Visalia Rollerblader Suffered Major Injuries After Being Struck by Vehicle

UP NEXT

Fresno County Man Indicted for Possessing Stolen Guns

UP NEXT

On Elon Musk’s X, Dems Are an Endangered Species While GOP Goes Viral

UP NEXT

New Vehicles, Face Paint and a 1,200-Foot Fall: The US Army Prepares for War With China

UP NEXT

CNN Bars Pro-Trump Guest After His ‘Beeper’ Remark to Mehdi Hasan

UP NEXT

LGBTQ Supporters Drown Out Westboro Baptists’ Anti-Gay Message in Fresno

UP NEXT

The ‘Black Insurrectionist’ Was Actually White. The Deception Did Not Stop There

UP NEXT

Washington Post Says It Will Stop Endorsing Presidential Candidates

UP NEXT

What Happened When a Barber Told Trump About His $15,000 Electric Bill

You May Have Blocked Someone on X but Now They Can See Your Public Posts Anyway

56 mins ago

Some Republican-Led States Refuse to Let Justice Department Monitors Into Polling Places

1 hour ago

Fresno Police Arrest Suspect in Fatal NW Apartment Shooting

2 hours ago

Fresno Murder Suspect Stopped in Las Vegas, Others Wanted

2 hours ago

Trump’s Crowds Are Dwindling as His Campaign Winds Down

2 hours ago

Trump Threatens 25% Tariff on Mexico to Curb Immigration

3 hours ago

Music Legend Quincy Jones, Architect of Pop’s Greatest Hits, Dies at 91

3 hours ago

Big Pharma Backs Harris 6-to-1 Over Trump in Presidential Campaign Contributions

3 hours ago

Sanger Men Arrested in Connection with Slingshot Vandalism Spree at Businesses

3 hours ago

What Is Sierra Unified’s Plan to Boost Lagging Student Achievement?

4 hours ago

5 Reasons Early Voting Is Overwhelmed With Falsehoods

This year’s early voting period appears to be far more polluted with election misinformation than those in previous presidential races, acco...

30 mins ago

Voters cast their ballots at Desert Breeze Community Center in Las Vegas during the last day of in-person early voting in Nevada on Friday, Nov. 1, 2024. Nearly 75 million people have cast early ballots, making their voices heard amid worry about the process, the outcome and democracy itself. (Bridget Bennett/The New York Times)
30 mins ago

5 Reasons Early Voting Is Overwhelmed With Falsehoods

38 mins ago

Christian McCaffrey Returns to Practice for the 49ers From Achilles Tendon Injury

43 mins ago

California Sues LA Suburb for Temporary Ban of Homeless Shelters

56 mins ago

You May Have Blocked Someone on X but Now They Can See Your Public Posts Anyway

1 hour ago

Some Republican-Led States Refuse to Let Justice Department Monitors Into Polling Places

Gerrick Franklin (pictured), 34, was taken into custody Sunday in Madera County on suspicion of killing Tyler Hamon, 33. (Fresno PD)
2 hours ago

Fresno Police Arrest Suspect in Fatal NW Apartment Shooting

2 hours ago

Fresno Murder Suspect Stopped in Las Vegas, Others Wanted

Former President Donald Trump, the Republican presidential nominee, on stage during a campaign rally in Lititz, Pa., on Sunday, Nov. 3, 2024. Trump told supporters on Sunday that he “shouldn’t have left” the White House at the end of his term during an end-of-campaign rally where he vented angrily about a spate of new public polls showing him losing ground to Vice President Kamala Harris and joked about reporters being shot at. (Doug Mills/The New York Times)
2 hours ago

Trump’s Crowds Are Dwindling as His Campaign Winds Down

Search

Send this to a friend